Allchem Lifescience IPO, a book-built/mainboard issue with SEBI’s approval, is raising capital with a fresh issue worth ₹190.00 crore and an offer-for-sale of 7,155,000 Equity Shares, face value at ₹10/share.
Allchem Lifescience Ltd has proposed the listing of IPO shares on BSE & NSE. Further information will be available after official publication.
Allchem Lifescience IPO–Details
| IPO Open | – |
| IPO Close | – |
| Face value | ₹10/share |
| Price Band | – |
| Issue price | – |
| IPO Lot Size | – |
| Offer-for-sale | 7,155,000 Equity Shares |
| Fresh issue | ₹190.00 crore |
| Issue Type | Mainboard/Book-built Issue |
| Listing | BSE & NSE |
| Total Issue Size (₹ Crore) | – |
| Minimum Retail Investment | – |
Allchem Lifescience IPO–Timeline
The Allchem Lifescience IPO timeline has not been released yet.
Allchem Lifescience Limited–Key Performance Indicators (KPIs)
| KPIs | 2024 | 2023 | 2022 |
| ROE (%) | 34.33 | 37.84 | 48.69 |
| ROCE (%) | 22.87 | 23.49 | 35.76 |
| Debt-Equity Ratio (in times) | 1.31 | 1.72 | 1.28 |
| RoNW (%) | 34.33 | 37.84 | 48.69 |
| PAT Margin (%) | 17.03 | 17.02 | 13.08 |
| EBITDA Margin (%) | 38.05 | 28.8 | 23.05 |
| Price-Book Value | – | – | – |
Allchem Lifescience Ltd–Financial Information
| 2024 (in ₹ crore) | 2023 (in ₹ crore) | 2022 (in ₹ crore) | |
| Revenue | 137.42 | 105.72 | 108.10 |
| Assets | 224.65 | 186.68 | 124.02 |
| Profit After Tax | 23.41 | 17.99 | 14.14 |
Allchem Lifescience IPO–Subscription Status
*Subscription data unavailable.
Subscription details will be released after bidding opens.
Application time on the subscription dates is between 10:00 AM and 5:00 PM.
Allchem Lifescience IPO–Grey Premium Market (GMP)
The grey market premium trend has not started yet for the Allchem Lifescience IPO. GMP updates will be available closer to the opening of the issue.
Allchem Lifescience IPO–Reservation
| Investor Category | % of Shares Offered |
| QIBs | Maximum 50% |
| Non-institutional Investors (NIIs) | Minimum 35% |
| Individual Investor | Minimum 15% |
| Total | 100% |
Allchem Lifescience IPO–Lot Size
Details regarding the Allchem Lifescience IPO are yet to be disclosed. It will be updated once the company shares the details.
Allchem Lifescience IPO–Anchor Investors Details
Information on anchor investors is currently missing and will be included once the company provides clarity.
Allchem Lifescience IPO–Prospectus
| Draft Red Herring Prospectus (DRHP) | DRHP Document |
| Red Herring Prospectus (RHP) | RHP Document (to be updated soon) |
About Allchem Lifescience Limited
The company, incorporated on 12 January 2017, operates as an Indian manufacturer of API intermediates and specialty chemicals, under the Chairman and Managing Director, Bipin Patel. The company’s operations focus on producing key starting materials (KSMs), generic API intermediates, and a range of specialty chemical products used across industries.
The company’s business verticals are divided into two segments:
- The first includes API intermediates, which serve as essential compounds in the process of manufacturing finished pharmaceutical ingredients.
- The second covers specialty chemicals, which are tailored for specific industrial applications and produced in smaller volumes with a focus on performance and precision, including their use in pharmaceutical synthesis processes.
| Book Running Lead Managers (BRLM) | Emkay Global Financial Services Ltd |
| IPO Registrar | MUFG Intime India Pvt Ltd |
Objectives of Allchem Lifescience IPO
| Particulars | Amount (in ₹ crore) |
| Repayment of borrowings | 130.00 |
| Corporate requirements | – |
Allchem Lifescience Limited–Strengths
- Established customer relationships: The company has built long-term ties with domestic and global pharmaceutical and chemical players, serving a wide and consistent client base across recent years.
- Growing customer reach: The company serves customers across multiple Indian states and international markets, which reflects a diversified presence and export orientation.
- Sustainable manufacturing setup: The company’s manufacturing facility is equipped with advanced machinery and adequate capacity, which enables efficient production of a wide range of chemical products.
- Focus on product development: The company continues to expand its product mix through ongoing work in new chemical formulations, supported by its experienced leadership and R&D team.
Allchem Lifescience Limited–Risks
- High dependence on the pharmaceutical sector: A major share of the company’s revenue is linked to the pharmaceutical industry, which makes its business sensitive to any slowdown in this segment.
- Reliance on a few customers: The company’s significant portion of revenue comes from a limited number of clients, and the absence of long-term contracts adds uncertainty to continuity.
- Geographical concentration of revenue: The company’s operations and earnings are concentrated in specific regions, which may affect performance if conditions in these areas weaken.
- Dependence on limited suppliers: The company relies on a few vendors without long-term agreements, and any disruption in raw material supply could impact operations and costs.
Allchem Lifescience IPO–Review
The Allchem Lifescience IPO reflects a mid-sized chemical manufacturer with a presence in API intermediates and specialty chemicals. The company’s financials show consistent growth in revenue and profitability, supported by improving margins. It focuses on product development and export markets, which adds to its positioning.
However, high dependence on the pharmaceutical sector and concentration among a few sets of customers remain areas to monitor. The absence of long-term contracts and reliance on select suppliers may also affect stability. Investors may consider both growth visibility and concentration risks while evaluating the offer.
Other Recent IPO List
Here are more Indian IPOs that are open now and upcoming in 2026!
| GSP Crop Science IPO | Raajmarg Infra Trust IPO |
| Novus Loyalty IPO | Innovision IPO |
| Apsis Aerocom IPO | Rajputana Stainless IPO |
| Skyways Air Services IPO | Srinibas Pradhan Construction IPO |
Allchem Lifescience IPO FAQs
The Allchem Lifescience IPO is a mainboard, book-built public issue through which the company plans to raise capital through a fresh issue (₹190.00 crore) along with an offer-for-sale of 7,155,000 equity shares. The proceeds are primarily intended for debt repayment and general corporate purposes.
To apply for the Allchem Lifescience IPO, investors can place bids through the ASBA facility using their bank account or apply via a registered stockbroker. Applications can also be made through UPI-enabled platforms within the IPO bidding window between 10:00 AM and 5:00 PM.
The Allchem Lifescience IPO presents a company with improved financial performance and a presence in essential chemical segments. However, risks such as dependence on the pharmaceutical industry and customer concentration remain. Investors may weigh growth prospects against these business risks before making a decision.
The Allchem Lifescience IPO expected returns cannot be determined at this stage, as details such as price band and GMP are not available yet. The returns will depend on valuation, investor demand, and overall market conditions at the time of listing.
The Allchem Lifescience IPO opening date has not been announced yet.
The Allchem Lifescience IPO lot size has not been disclosed so far.
The Allchem Lifescience IPO share allotment date is yet to be announced.
The Allchem Lifescience IPO listing date has not been confirmed yet. The shares are expected to be listed on the BSE and NSE following the completion of the allotment process, as per standard IPO timelines.
